Jasmeer P. Chhatwal

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease

This study evaluates how biomarker variability affects individualized amyloid time estimation in Alzheimer's disease, finding that inter-individual variability is the main source of error.

Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's Disease

The paper identifies gene associations with plasma pTau217 in preclinical Alzheimer's disease, showing modulation by APOEε4, Aβ-PET, and sex, with X-linked genes playing a role.

CNS-Tau Specific Antibodies Illuminate Disease Signatures Across Tauopathies

The paper develops and validates CNS-tau-specific monoclonal antibodies for use in neuropathology and plasma biomarker assays across Alzheimer's disease and primary tauopathies.

Systematic analysis of cellular crosstalk reveals a role for SEMA6D-TREM2 regulating microglial function in Alzheimer's disease

The paper investigates cell-to-cell communication in Alzheimer's disease to characterize disease biology and suggest new avenues for therapeutic intervention.

The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1

The paper assesses the pathogenicity of PSEN2 variants by comparing Aβ production and homology to PSEN1 variants, finding correlations with age at symptom onset.

Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer's Disease Therapy

This study identifies fibrinogen as a plasma protein binding partner for lecanemab biosimilar, suggesting it may affect drug half-life and free antibody levels in Alzheimer's disease therapy.

Functional variations in gamma-secretase activity are critical determinants of the clinical, biomarker, and cognitive progression of autosomal dominant Alzheimer's disease

The paper quantifies Aβ production from PSEN1 variants and links it to clinical and biomarker progression in ADAD, showing strong associations with disease trajectories.

A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer's disease

The paper presents a high-quality quantitative proteomics dataset for Alzheimer's disease, including samples from different brain regions and clinical groups.

Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI

The paper describes MRI and PET protocols used in the DIAN study to investigate preclinical Alzheimer's disease and reports key imaging findings.

Circular RNA detection identifies circPSEN1 alterations in brain specific to Autosomal Dominant Alzheimer Disease

This study identifies increased circPSEN1 levels in ADAD brains compared to sporadic AD and controls, suggesting a potential role in neuroinflammatory processes.

Spontaneous Isomerization of Asp387 in Tau is Diagnostic for Alzheimer's Disease: An Endogenous Indicator of Reduced Autophagic Flux

The paper identifies isomerization of Asp387 in tau as a marker of reduced autophagic flux in Alzheimer's disease using mass spectrometry analysis of brain tissue.

Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer disease brains

This study identifies metabolomic and lipidomic signatures in Alzheimer's disease brains with different genetic risk factors and finds associations with disease subtypes and progression.

Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology

The paper develops a model to predict brain aging from resting state fMRI and finds accelerated brain aging in preclinical Alzheimer's disease, independent of amyloid-beta pathology.